{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T11:38:45Z","timestamp":1788089925141,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,22]]},"DOI":"10.7759\/cureus.109423","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:35:31Z","timestamp":1779453331000},"source":"Crossref","is-referenced-by-count":1,"title":["Targeted Therapy in Erdheim-Chester Disease: A Case Report and Review of the Literature"],"prefix":"10.7759","author":[{"given":"Ammar","family":"Alromdhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yagnapriya","family":"Ammakola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Cantu Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasey","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Fullmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Chisti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11629","article-title":"Erdheim-Chester disease: comprehensive review of molecular profiling and therapeutic advances","volume":"37","author":"Haroun F","year":"2017","unstructured":"Haroun F, Millado K, Tabbara I. Erdheim-Chester disease: comprehensive review of molecular profiling and therapeutic advances. Anticancer Res. 2017, 37:2777-83. 10.21873\/anticanres.11629","journal-title":"Anticancer Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00199","article-title":"Clinical activity of mitogen-activated protein kinase inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers","volume":"9","author":"Dankner M","year":"2025","unstructured":"Dankner M, Rousselle E, Petrecca S, et al.. Clinical activity of mitogen-activated protein kinase inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers. JCO Precis Oncol. 2025, 9:e2400199. 10.1200\/PO.24.00199","journal-title":"JCO Precis Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00311-1","article-title":"Histiocytosis","volume":"398","author":"Emile JF","year":"2021","unstructured":"Emile JF, Cohen-Aubart F, Collin M, et al.. Histiocytosis. Lancet. 2021, 398:157-70. 10.1016\/S0140-6736(21)00311-1","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002766","article-title":"Erdheim-Chester disease","volume":"135","author":"Haroche J","year":"2020","unstructured":"Haroche J, Cohen-Aubart F, Amoura Z. Erdheim-Chester disease. Blood. 2020, 135:1311-8. 10.1182\/blood.2019002766","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2020.101510","article-title":"Erdheim-Chester disease","volume":"34","author":"Starkebaum G","year":"2020","unstructured":"Starkebaum G, Hendrie P. Erdheim-Chester disease. Best Pract Res Clin Rheumatol. 2020, 34:101510. 10.1016\/j.berh.2020.101510","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0944-4","article-title":"Erdheim-Chester disease: a rapidly evolving disease model","volume":"34","author":"Pegoraro F","year":"2020","unstructured":"Pegoraro F, Papo M, Maniscalco V, Charlotte F, Haroche J, Vaglio A. Erdheim-Chester disease: a rapidly evolving disease model. Leukemia. 2020, 34:2840-57. 10.1038\/s41375-020-0944-4","journal-title":"Leukemia"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2024.101845","article-title":"Erdheim-Chester disease: comprehensive insights from genetic mutations to clinical manifestations and therapeutic advances","volume":"71","author":"Chaudhary R","year":"2025","unstructured":"Chaudhary R, Kumar A, Singh A, et al.. Erdheim-Chester disease: comprehensive insights from genetic mutations to clinical manifestations and therapeutic advances. Dis Mon. 2025, 71:101845. 10.1016\/j.disamonth.2024.101845","journal-title":"Dis Mon"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00256-024-04835-9","article-title":"Radiological assessment of extremity bone involvement in Erdheim-Chester disease: a systematic review of case reports","volume":"54","author":"Azhideh A","year":"2025","unstructured":"Azhideh A, Pouramini A, Haseli S, Abbaspour E, Karande G, Kafi F, Chalian M. Radiological assessment of extremity bone involvement in Erdheim-Chester disease: a systematic review of case reports. Skeletal Radiol. 2025, 54:1441-55. 10.1007\/s00256-024-04835-9","journal-title":"Skeletal Radiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016001784","article-title":"The clinical spectrum of Erdheim-Chester disease: an observational cohort study","volume":"1","author":"Estrada-Veras JI","year":"2017","unstructured":"Estrada-Veras JI, O'Brien KJ, Boyd LC, et al.. The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv. 2017, 1:357-66. 10.1182\/bloodadvances.2016001784","journal-title":"Blood Adv"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2025.114440","article-title":"BRAF V600E in cancer: exploring structural complexities, mutation profiles, and pathway dysregulation","volume":"446","author":"Bharti J","year":"2025","unstructured":"Bharti J, Gogu P, Pandey SK, et al.. BRAF V600E in cancer: exploring structural complexities, mutation profiles, and pathway dysregulation. Exp Cell Res. 2025, 446:114440. 10.1016\/j.yexcr.2025.114440","journal-title":"Exp Cell Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5029","article-title":"Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study","volume":"4","author":"Diamond EL","year":"2018","unstructured":"Diamond EL, Subbiah V, Lockhart AC, et al.. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol. 2018, 4:384-8. 10.1001\/jamaoncol.2017.5029","journal-title":"JAMA Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01947-4","article-title":"CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1\/2 inhibition","volume":"37","author":"Diamond EL","year":"2023","unstructured":"Diamond EL, Francis JH, Lacouture ME, et al.. CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1\/2 inhibition. Leukemia. 2023, 37:1737-40. 10.1038\/s41375-023-01947-4","journal-title":"Leukemia"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024028032","article-title":"Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease","volume":"145","author":"Goyal G","year":"2025","unstructured":"Goyal G, Reiner AS, Bossert D, et al.. Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease. Blood. 2025, 145:2100-3. 10.1182\/blood.2024028032","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-771873","article-title":"Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)","volume":"130","author":"Cohen Aubart F","year":"2017","unstructured":"Cohen Aubart F, Emile JF, Carrat F, et al.. Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). Blood. 2017, 130:1377-80. 10.1182\/blood-2017-03-771873","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18964","article-title":"Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms","volume":"203","author":"Reiner AS","year":"2023","unstructured":"Reiner AS, Durham BH, Yabe M, et al.. Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms. Br J Haematol. 2023, 203:389-94. 10.1111\/bjh.18964","journal-title":"Br J Haematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.185298","article-title":"Single-agent dabrafenib for BRAF(V600E)-mutated histiocytosis","volume":"103","author":"Bhatia A","year":"2018","unstructured":"Bhatia A, Ulaner G, Rampal R, et al.. Single-agent dabrafenib for BRAF(V600E)-mutated histiocytosis. Haematologica. 2018, 103:e177-80. 10.3324\/haematol.2017.185298","journal-title":"Haematologica"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","volume":"567","author":"Diamond EL","year":"2019","unstructured":"Diamond EL, Durham BH, Ulaner GA, et al.. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019, 567:521-4. 10.1038\/s41586-019-1012-y","journal-title":"Nature"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009013","article-title":"Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis","volume":"7","author":"Aaroe A","year":"2023","unstructured":"Aaroe A, Kurzrock R, Goyal G, et al.. Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis. Blood Adv. 2023, 7:3984-92. 10.1182\/bloodadvances.2022009013","journal-title":"Blood Adv"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-740217","article-title":"Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations","volume":"129","author":"Nordmann TM","year":"2017","unstructured":"Nordmann TM, Juengling FD, Recher M, et al.. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations. Blood. 2017, 129:879-82. 10.1182\/blood-2016-09-740217","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/487156-targeted-therapy-in-erdheim-chester-disease-a-case-report-and-review-of-the-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:35:31Z","timestamp":1779453331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/487156-targeted-therapy-in-erdheim-chester-disease-a-case-report-and-review-of-the-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.109423","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,22]]}}}